Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients

Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: محمد رضا جعفری نخجوانی , مهدی جعفرپور , امیر قربانی حق جو , سیما عابدی آذر , آیدا مالک مهدوی

کلمات کلیدی: Rheumatoid arthritis; advanced glycation end products (AGEs,); soluble receptor for AGEs (sRAGE); disease activity

نشریه: 24352 , 6 , 29 , 2019

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله آیدا مالک مهدوی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های بافت همبند
کد مقاله 69784
عنوان فارسی مقاله Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients
عنوان لاتین مقاله Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients
ناشر 5
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Objective: Considering the important role of serum soluble receptor for advanced glycation end product (sRAGE/RAGE)–ligand system in rheumatoid arthritis (RA), this study aimed to evaluate serum sRAGE levels in RA patients compared to healthy subjects and to assess whether there is an association between sRAGE levels and disease characteristics in RA. Methods: In this cross-sectional study, 60 RA patients according to the ACR/EULAR 2010 criteria and 30 age- and sex-matched healthy controls were included. In patients, clinical examination was performed and disease activity score 28 (DAS-28) measure of disease activity was assessed. Serum sRAGE level was measured using ELISA kit. Results: The mean ± SD age of patients and controls was 54.86 ± 11.65 and 50.71 ± 3.72 years, respectively). Serum sRAGE level was significantly higher in RA patients (median [25th and 75th percentiles], 1000.3 [792.00, 1486.8]) compared to healthy controls (median [25th and 75th percentiles], 293.25 [220.35, 364.24]) (p < .001). There was significant difference in serum sRAGE level according to the activity of disease (p < .001). There were significant positive correlations between serum sRAGE level with disease activity (r ¼ 0.67, p < .001), ESR (r ¼ 0.411, p ¼ .001) and CRP (r ¼ 0.273, p ¼ .035). There were no significant correlations between serum sRAGE level with demographic characteristics as well as biochemical measurements including serum creatinine, BUN, RF, and Anti-CCP (p > .05). Conclusions: Our study revealed higher serum sRAGE levels in RA patients compared to healthy controls, which correlated positively with disease activity.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
محمد رضا جعفری نخجوانیاول
مهدی جعفرپوردوم
امیر قربانی حق جوسوم
سیما عابدی آذرچهارم
آیدا مالک مهدویپنجم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Relationship between serum soluble receptor for advanced glycation end products sRAGE and disease activity in rheumatoid arthritis patients.pdf1398/08/221076443دانلود